The latest price target for Verrica Pharmaceuticals (NASDAQ:VRCA) was reported by RBC Capital on August 15, 2024. The analyst firm set a price target for $13.00 expecting VRCA to rise to within 12 months (a possible 562.49% upside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Verrica Pharmaceuticals (NASDAQ:VRCA) was provided by RBC Capital, and Verrica Pharmaceuticals maintained their outperform rating.

The last upgrade for Verrica Pharmaceuticals Inc happened on July 25, 2023 when Needham raised their price target to $10. Needham previously had a hold for Verrica Pharmaceuticals Inc.

The last downgrade for Verrica Pharmaceuticals Inc happened on May 25, 2022 when RBC Capital changed their price target from $16 to $4 for Verrica Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verrica Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verrica Pharmaceuticals was filed on August 15, 2024 so you should expect the next rating to be made available sometime around August 15, 2025.

While ratings are subjective and will change, the latest Verrica Pharmaceuticals (VRCA) rating was a maintained with a price target of $14.00 to $13.00. The current price Verrica Pharmaceuticals (VRCA) is trading at is $1.96, which is out of the analyst’s predicted range.